<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196820</url>
  </required_header>
  <id_info>
    <org_study_id>GBG 39</org_study_id>
    <secondary_id>Eudract Number: 2005-000074-51</secondary_id>
    <nct_id>NCT00196820</nct_id>
  </id_info>
  <brief_title>Mono Efficacy of Capecitabine (MoniCa)</brief_title>
  <official_title>A Multicenter Phase II Study to Determine the Efficacy of Capecitabine as First Line Monochemotherapy in Patients With HER2 Negative, Medium-risk, Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study done in patients with metastatic breast cancer in order to determine the efficacy of&#xD;
      capecitabine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      Prospective, open phase II trial&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Capecitabine 2000 mg/m² orally day 1-14 q day 22 until progression, unacceptable toxicity,&#xD;
      patient's request or withdrawal from study&#xD;
&#xD;
      Primary objective&#xD;
&#xD;
      To determine the time to disease progression in patients with HER2 negative metastatic breast&#xD;
      cancer after 1st line monochemotherapy with capecitabine&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        1. To determine the objective response rate&#xD;
&#xD;
        2. To determine the duration of response&#xD;
&#xD;
        3. To determine the clinical benefit defined as CR, PR, or stable disease ≥ 24 weeks&#xD;
&#xD;
        4. To evaluate the safety and toxicity of capecitabine&#xD;
&#xD;
        5. To assess quality of life within 1 year after start of capecitabine treatment&#xD;
&#xD;
        6. To determine overall survival&#xD;
&#xD;
        7. To determine the objective response rate in male patients&#xD;
&#xD;
        8. To evaluate QoL the modified Brunner Score (Appendix 7 )&#xD;
&#xD;
      Tertiary objective&#xD;
&#xD;
      To determine the DPD and Proteomics in serum&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any progression of disease or disease related death of a patient</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any response (partial and complete) documented according to the WHO Criteria (s. App 6),</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from complete or partial response until progression of disease or death due to any cause,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any response (partial and complete) and stable disease of &gt; 24 weeks duration documented according to the WHO Criteria (App. 6),</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any grade III/IV toxicity (NCI-CTC Version 2.0),</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature treatment discontinuation,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any dose reduction due to toxicity,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any death of a patient,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QoL and modified Brunner Score,</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent prior to beginning specific protocol procedures, including&#xD;
             expected cooperation of the patients for the treatment and follow-up, must be obtained&#xD;
             and documented according to the local regulatory requirements.&#xD;
&#xD;
          2. Histologically confirmed carcinoma of the breast.&#xD;
&#xD;
          3. Negative for HER2-overexpression of the primary and/or metastatic tumour tissue&#xD;
             detected by immunohistochemistry (DAKO 0-2) or genamplification detected by FISH.&#xD;
&#xD;
          4. Locally advanced or metastatic stage of disease not suitable for surgery or&#xD;
             radiotherapy alone.&#xD;
&#xD;
          5. The following previous systemic treatment are eligible:&#xD;
&#xD;
             adjuvant chemotherapy (except if capecitabine was included) adjuvant endocrine therapy&#xD;
             palliative endocrine treatments treatment with bisphosphonates (adjuvant and/or&#xD;
             palliative) treatment with immunotherapies (adjuvant and/or palliative)&#xD;
&#xD;
          6. Patients must have either measurable or nonmeasurable target lesions according to the&#xD;
             WHO criteria (see Appendix 5).&#xD;
&#xD;
          7. At least 4 weeks since radiotherapy, with full recovery. The measurable disease must&#xD;
             be completely outside the radiation portal or there must be pathologic proof of&#xD;
             progressive disease.&#xD;
&#xD;
          8. Complete radiology and tumor measurement work up within 4 weeks prior to registration.&#xD;
&#xD;
          9. Karnofsky performance status evaluation &gt; or = 60%&#xD;
&#xD;
         10. Age &gt;18 years&#xD;
&#xD;
         11. WBC &gt; or = 3000 cells/microl, platelet count &gt; or = 100,000 cells/microl.&#xD;
&#xD;
         12. Bilirubin &lt; or = 2x the upper limit of normal for the institution (ULN); elevation of&#xD;
             transaminases and alkaline phosphatase &lt; 2.5x ULN or &lt;5x ULN for patients with liver&#xD;
             metastases.&#xD;
&#xD;
         13. Creatinine &lt; or = 1,25 x upper normal value or creatinin-clearance &gt; 50 ml/min&#xD;
             (according to Cockroft Gault).&#xD;
&#xD;
         14. If of childbearing potential, negative pregnancy test. In addition the patient has to&#xD;
             agree to use an effective method to avoid pregnancy for the duration of the study.&#xD;
&#xD;
         15. Female and male patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity reaction to the compounds or incorporated substances or known&#xD;
             dihydropyrimidine dehydrogenase deficiency.&#xD;
&#xD;
          2. Concurrent immunotherapy or hormonal therapy (antihormonal, contraceptive and/or&#xD;
             replacement therapy). Bisphosphonates may be continued.&#xD;
&#xD;
          3. Parenchymal brain metastases, unless adequately controlled by surgery and/or&#xD;
             radiotherapy with complete resolution of symptoms and discontinuation of all steroids.&#xD;
&#xD;
          4. Life expectancy of less than 3 months.&#xD;
&#xD;
          5. Serious intercurrent medical or psychiatric illness that may interfere with the&#xD;
             planned treatment (including AIDS and serious active infection).&#xD;
&#xD;
          6. History of other malignancy within the last 5 years which could affect the diagnosis&#xD;
             or assessment of metastatic breast cancer.&#xD;
&#xD;
          7. Patients with indication for polychemotherapy.&#xD;
&#xD;
          8. Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational not marketed drug within 30 days prior to study entry.&#xD;
&#xD;
          9. Treatment with sorivudine or derivates e.g. brivudin.&#xD;
&#xD;
         10. Pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Kaufmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der J. W. Goethe Universität, Universitätsfrauenklinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>J. W. Goethe Universität, Frauenklinik</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.germanbreastgroup.de</url>
    <description>Click here for more information about this study: MoniCa Study</description>
  </link>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>HER2 negative, medium-risk, metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

